Molecular engineering of antibodies for therapeutic and diagnostic purposes
Molecular engineering of antibodies for therapeutic and diagnostic purposes
复制标题
DOI：
10.4161/mabs.20776
复制
发表时间：
2012-07-01
期刊：
影响因子：
5.3
通讯作者：
Muller, Bruno H.
中科院分区：
文献类型：
--
作者：
Ducancel, Frederic;Muller, Bruno H.
在过去的十年中，单克隆抗体（mab）在靶向治疗和诊断领域占据了中心位置。这种对单克隆抗体的兴趣增加是由于它们的结合准确性（亲和力和特异性）以及控制与其同源抗原相互作用的原始分子和结构规则。此外，抗体的效应特性构成了其临床应用的第二个主要优势。分子和结构工程的发展以及最近抗体的体外进化为更适合临床和诊断使用的抗体的从头设计开辟了新的视角。因此，研究人员经常努力改善或调节抗体识别特性，调整其药代动力学，设计其稳定性并控制其免疫原性。本文综述了单克隆抗体在治疗和诊断方面的最新分子工程研究成果。
During the past ten years, monoclonal antibodies (mAbs) have taken center stage in the field of targeted therapy and diagnosis. This increased interest in mAbs is due to their binding accuracy (affinity and specificity) together with the original molecular and structural rules that govern interactions with their cognate antigen. In addition, the effector properties of antibodies constitute a second major advantage associated with their clinical use. The development of molecular and structural engineering and more recently of in vitro evolution of antibodies has opened up new perspectives in the de novo design of antibodies more adapted to clinical and diagnostic use. Thus, efforts are regularly made by researchers to improve or modulate antibody recognition properties, to adapt their pharmacokinetics, engineer their stability and control their immunogenicity. This review presents the latest molecular engineering results on mAbs with therapeutic and diagnostic applications.